Trestolone
Extensively StudiedPopulation Council male contraceptive candidate — that's the giveaway. | AAS · Oil injectable
Aliases (5)
▸ Vial inspection & sterile draw AAS oil
AAS oil arrives pre-suspended in carrier oil — no BAC water needed. Inspect for clarity, color, and crashed compound (cold storage can crystallize). Warm vial in palm or under hot tap before draw.
- 1 Wipe vial stopper with isopropyl alcohol.
- 2 Warm vial 30-60s in palm if oil is cold/cloudy.
- 3 Draw with 18g needle into 22-25g pin barrel for IM, or 27-29g for sub-Q.
- 4 Tap out air bubbles, expel a small drop, then inject at chosen site.
▸ Cycle structure & PCT AAS
Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.
On the last dose, the ester clears over its half-life window (acetate = est. ~7 days). PCT begins after the active compound has cleared.
Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).
▸ Overview TL;DR
Population Council male contraceptive candidate — that's the giveaway. Anything designed to shut down sperm production in healthy adult males via full HPG suppression is a hard SKIP for a 20yo developing endocrine system. ~10× testosterone potency, non-5α-reducible, but aromatizes. No brain benefit, WADA-banned, gray-market only. Permanent skip until ~30+ with full bloodwork history.
▸ Mechanism of action
- 19-nor structure: Like nandrolone, the 19-carbon is removed. Reduces androgenic-to-anabolic ratio shift, weakens DHT-mediated effects.
- 7α-methyl group: Blocks 5α-reductase conversion (no DHT, no scalp/prostate DHT exposure) AND blocks 3α-HSD oxidative deactivation. Result: extremely high AR potency per mg.
- Aromatization: Unlike most 19-nors, MENT aromatizes to 7α-methylestradiol — a potent estrogen. AI's are still required to manage E2; this is NOT a "dry" compound.
- Progesterone receptor: Weak PR binding (less than nandrolone), but enough to potentiate suppression alongside the estrogen feedback. This is part of why suppression is so complete and rapid.
- HPG-axis effect: Within days of supraphysiologic dosing, LH and FSH crash. Endogenous testosterone production halts. Intratesticular testosterone drops to azoospermic levels — this IS the contraceptive mechanism.
- Potency: ~10× testosterone by mass on AR binding/anabolic assays. Translation: 1 mg MENT ≈ 10 mg testosterone for tissue-level AR signaling.
▸ Pharmacokinetics No data
▸Research indications6 use cases
19-nor structure
Most effectiveLike nandrolone, the 19-carbon is removed. Reduces androgenic-to-anabolic ratio shift, weakens DHT-mediated effects.
7α-methyl group
EffectiveBlocks 5α-reductase conversion (no DHT, no scalp/prostate DHT exposure) AND blocks 3α-HSD oxidative deactivation. Result: extremely high …
Aromatization
EffectiveUnlike most 19-nors, MENT aromatizes to 7α-methylestradiol — a potent estrogen. AI's are still required to manage E2; this is NOT a "dry"…
Progesterone receptor
ModerateWeak PR binding (less than nandrolone), but enough to potentiate suppression alongside the estrogen feedback. This is part of why suppres…
HPG-axis effect
ModerateWithin days of supraphysiologic dosing, LH and FSH crash. Endogenous testosterone production halts. Intratesticular testosterone drops to…
Potency
Moderate~10× testosterone by mass on AR binding/anabolic assays. Translation: 1 mg MENT ≈ 10 mg testosterone for tissue-level AR signaling.
▸Research protocols3 protocols
| Goal | Dose | Frequency | Solo | Cycle |
|---|---|---|---|---|
| Contraceptive (Population Council) | 400 μg/day via subdermal implant | — | — | — |
| Bodybuilding (gray-market, NOT clinical) | 50-100 mg/week trestolone acetate (TNE-style daily injections of 10-15 mg/day common due to short ester half-life) | — | — | — |
| TRT replacement (experimental) | 25-50 mg/week — controversial | — | — | — |
Auto-extracted from dosing notes. For full context including caveats and Dylan-specific protocols, see the Dosing protocols section.
▸Quality indicators5 checks
▸ What to expect Generic
- 1Week 1-2Frontload phase. Strength gains start; appetite up.
- 2Week 3-4Visible muscle fullness and recovery acceleration.
- 3Week 5-8Peak performance window. Monitor blood pressure + libido.
- 4Post-cyclePCT week 1-4. Bloodwork at week 6 post-cycle.
▸ Side effects + safety
- Common (>10% users):
- Full HPG-axis shutdown (universal)
- Libido oscillation
- Acne (high AR potency)
- Water retention / mild gyno risk if no AI
- Lipid changes — HDL crash, LDL elevation (typical 19-nor profile, possibly worse due to potency)
- Less common (1-10%):
- Mood lability, aggression
- Hair shedding (despite no DHT — AR signaling at follicle still occurs)
- Hematocrit elevation
- Sleep disruption, night sweats
- Rare-serious (<1% but worth knowing):
- Gynecomastia requiring surgical correction
- Prolonged HPG-axis recovery (months to never returning to baseline) — risk increases with cycle length, age at first use, prior cycles
- Cardiovascular: lipid-mediated atherogenic shift; LVH on chronic high-dose
- Hepatotoxicity is LOW — MENT is not C17α-alkylated, so injectable use is liver-friendly (unlike oxandrolone). Transdermal/subdermal forms are also liver-sparing.
- Specific watch periods: First 4-8 weeks for E2 management; entire cycle + 6+ months post for HPG-axis recovery
▸Interactions3 compounds
- Any other AASAvoidadditive HPG suppression, additive lipid/cardiovascular damage
- Other 19-nors (nandrolone, trenbolone)Avoidoverlapping PR binding, more progestogenic gyno risk
- Oral 17α-alkylated AAS (oxandrolone, etc.)Avoidadditive lipid/hepatic stress